Monte Rosa Therapeutics, Inc. Common Stock vs. Krystal Biotech, Inc. Common Stock
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
$12.13 -3.73%
VS KRYSKrystal Biotech, Inc. Common Stock
$336.67 -0.61%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| GLUE | KRYS | |
|---|---|---|
| Market Cap | $1.03 billion | $9.97 billion |
| Revenue (TTM) | — | $440.48 million |
| Net Income (TTM) | $-161,090,000 | $241.47 million |
KRYS leads on 2 of 2 size & scale factors.
Valuation
| GLUE | KRYS | |
|---|---|---|
| P/E Ratio | — | 42.19 |
| Price / Book | 2.12 | 7.33 |
| Price / Sales | — | 22.62 |
GLUE leads on 1 of 1 valuation factors.
Profitability
| GLUE | KRYS | |
|---|---|---|
| Net Margin | — | 54.82% |
| Return on Equity | -33.06% | 17.77% |
KRYS leads on 1 of 1 profitability factors.
Risk & Sentiment
| GLUE | KRYS | |
|---|---|---|
| Short Interest | 0.86% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: GLUE overview, GLUE financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.